Characteristics of patients prescribed angiotensin-converting enzyme inhibitors, angiotensin blockers, or the combination at an urban medical center

MedGenMed Medscape General Medicine

Volumn 9, Issue 4, 2007, Pages

  Masri, Ghania ^a   Bledsoe, Kristi ^b   Palacio, Carlos ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; INSULIN; LOOP DIURETIC AGENT; SULFONYLUREA; THIAZIDE DIURETIC AGENT;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CHI SQUARE TEST; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POST HOC ANALYSIS; PREDICTION; RENAL PROTECTION; RETROSPECTIVE STUDY; URBAN AREA; AGED; BLOOD PRESSURE MEASUREMENT; COHORT ANALYSIS; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; FOLLOW UP; HOSPITALIZATION; MIDDLE AGED; PROBABILITY; RISK ASSESSMENT; STATISTICAL MODEL; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; URBAN POPULATION;

ACADEMIC MEDICAL CENTERS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE DETERMINATION; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LINEAR MODELS; MALE; MIDDLE AGED; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URBAN POPULATION;

EID: 36348965916     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Kjeldsen SE, Julius S. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am Heart J. 2004;148:747-754.
2. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356:1955-1964.
3. Ruilope LM, Coca A, Volpe M, Waeber B. ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations? Am J Hypertens. 2002; 15(pt1):367-371.
4. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305-1315.
5. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol. 2002;89:3A-9A.
6. Urata H, Nishimura H, Ganten D. Chymase-dependent angiotensin II forming systems in humans. Am J Hypertens. 1996;9:277-284.
7. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999;100:1056-1064.
8. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
9. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol. 2002;89:18A-25A.
10. Jacobsen P, Rossing K, Parving HH. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/ or angiotensin II receptor blockers) in diabetic nephropathy. Curr Opin Nephrol Hypertens. 2004; 13:319-324.
11. Cohen JD. Managing hypertension: state of the science. J Clin Hypertens (Greenwich). 2006;8(suppl3):5-11.